Search

Your search keyword '"Fazio, Nicola"' showing total 1,096 results
Start Over Author "Fazio, Nicola"
1,096 results on '"Fazio, Nicola"'

3. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis

Author

Rubino, Manila, Di Stasio, Giuseppe Danilo, Bodei, Lisa, Papi, Stefano, Rocca, Paola Anna, Ferrari, Mahila Esmeralda, Fodor, Cristiana Iuliana, Bagnardi, Vincenzo, Frassoni, Samuele, Mei, Riccardo, Fazio, Nicola, Ceci, Francesco, and Grana, Chiara Maria

Published
2024
Full Text
View/download PDF

4. Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database

Author

Panzuto, Francesco, Partelli, Stefano, Campana, Davide, de Braud, Filippo, Spada, Francesca, Cives, Mauro, Tafuto, Salvatore, Bertuzzi, Alexia, Gelsomino, Fabio, Bergamo, Francesca, Marcucci, Stefano, Mastrangelo, Laura, Massironi, Sara, Appetecchia, Marialuisa, Filice, Angelina, Badalamenti, Giuseppe, Bartolomei, Mirco, Amoroso, Vito, Landoni, Luca, Rodriquenz, Maria Grazia, Valente, Monica, Colao, Annamaria, Isidori, Andrea, Fanciulli, Giuseppe, Bollina, Roberto, Ciola, Michele, Butturini, Giovanni, Marconcini, Riccardo, Arvat, Emanuela, Cinieri, Saverio, Berardi, Rossana, Baldari, Sergio, Riccardi, Ferdinando, Spoto, Chiara, Giuffrida, Dario, Gattuso, Domenico, Ferone, Diego, Rinzivillo, Maria, Bertani, Emilio, Versari, Annibale, Zerbi, Alessandro, Lamberti, Giuseppe, Lauricella, Eleonora, Pusceddu, Sara, Fazio, Nicola, Dell’Unto, Elisabetta, Marini, Marco, and Falconi, Massimo

Published
2024
Full Text
View/download PDF

8. Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group

Author

Fazio, Nicola, Falconi, Massimo, Foglia, Emanuela, Bartolomei, Mirco, Berruti, Alfredo, D’Onofrio, Mirko, Ferone, Diego, Giordano, Alessandro, Grimaldi, Franco, Milione, Massimo, Panzuto, Francesco, Santimaria, Monica, Schillaci, Orazio, Seregni, Ettore, Stasi, Michele, Volante, Marco, and Lastoria, Secondo

Published
2024
Full Text
View/download PDF

13. Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial

Author

Ligero, Marta, Hernando, Jorge, Delgado, Eric, Garcia-Ruiz, Alonso, Merino-Casabiel, Xavier, Ibrahim, Toni, Fazio, Nicola, Lopez, Carlos, Teulé, Alexandre, Valle, Juan W., Tafuto, Salvatore, Custodio, Ana, Reed, Nicholas, Raderer, Markus, Grande, Enrique, Garcia-Carbonero, Rocio, Jimenez-Fonseca, Paula, Garcia-Alvarez, Alejandro, Escobar, Manuel, Casanovas, Oriol, Capdevila, Jaume, and Perez-Lopez, Raquel

Published
2023
Full Text
View/download PDF

18. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Mendez, Guillermo, O'Connor, Juan Manuel, Yanzi Castilla, Alvaro, Cundom, Juan, Kaen, Diego, Wong, Rachel, Ng, Weng, Aghmesheh, Morteza, Peressoni, Mauricio, Andrade, Carlos, Franke, Fabio, Alves, Gustavo, Cruz, Felipe Jose, Vianna, Karina, Monteiro, Maria Marcela, Raphael, Michael, Berry, Scott, Jang, Raymond, Tan, Ann, Asselah, Jamil, Yanez Weber, Patricio, Mahave, Mauricio, Sanchez, Cesar, Salman, Pamela, Bai, Yuxian, Li, Jin, Zhang, Xiaochun, Liu, Tianshu, Lin, Xiaoyan, Qin, Shukui, Yang, Jianwei, Luo, Suxia, Li, Wei, Ying, Jieer, Chen, Xi, Zeng, Shan, Qu, Yanli, Yang, Lin, Zhao, Lin, Chen, Ping, Pan, Hongming, Li, Enxiao, Ye, Feng, Lu, Jianwei, Liang, Xinjun, Zhao, Qun, Yin, Xianli, Li, Junhe, Ling, Yang, Lv, Guoqing, Li, Shouguo, Guerrero, Alvaro, Rubiano, Juan, Gonzalez Fernandez, Manuel, Manneh Kopp, Ray, Guzman Ramirez, Adrian, Corrales, Luis, Gonzalez Herrera, Ileana, Melichar, Bohuslav, Buchler, Tomas, Svoboda, Tomas, Obermannova, Radka, Vrana, David, Cvek, Jakub, Pfeiffer, Per, Baeksgaard, Lene, Yilmaz, Mette, Boige, Valerie, Lopez-Trabada, Daniel, Borg, Christophe, Pannier, Diane, Hiret, Sandrine, Di Fiore, Frederic, Metges, Jean-Philippe, Arnold, Dirk, Martens, Uwe, Lordick, Florian, Stein, Alexander, Castro, Hugo, Lopez, Karla, Ramirez, Julio, Aguilar, Mynor, Chivalan, Marco, Chan, Wendy, Cheng, Ashley, Yeo, Winnie, Arkosy, Peter, Csoszi, Tibor, Hitre, Erika, Horvath, Zsolt, Lowery, Maeve, McDermott, Ray, Morris, Patrick, Hubert, Ayala, Brenner, Baruch, Ben-Aharon, Irit, Shacham-Shmueli, Einat, Man, Sofia, Pelles Avraham, Sharon, Brenner, Ronen, Mishaeli, Moshe, Di Bartolomeo, Maria, Fazio, Nicola, Lonardi, Sara, Garufi, Carlo, Satoh, Taroh, Hara, Hiroki, Iwagami, Shiro, Yasui, Hisateru, Tsuda, Masahiro, Shimoyama, Tatsu, Shoji, Hirokazu, Sugimoto, Naotoshi, Shibata, Nobuhiro, Yamaguchi, Kensei, Amagai, Kenji, Choda, Yasuhiro, Esaki, Taito, Yabusaki, Hiroshi, Oshima, Takashi, Tsuji, Akihito, Kawakami, Hisato, Kawazoe, Akihito, Ishido, Kenji, Kadowaki, Shigenori, Martinez Rodriguez, Jorge, Herrera Martinez, Marytere, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Balancan, Paola, Damianovich, Dragan, Castro Oliden, Victor, Grados, Julio, Torres, Cesar, Wyrwicz, Lucjan, Wysocki, Piotr, Hajac, Lukasz, Zolnierek, Jakub, Karaszewska, Boguslawa, Rha, Sun Young, Lee, Jeeyun, Ryu, Min-Hee, Oh, Do-Youn, Orlova, Rashida, Tjulandin, Sergey, Fadeeva, Natalia, Makarycheva, Yulia, Nosov, Dmitry, Smagina, Maria, Chan, Sze, Jacobs, Conrad, Kraus, Peter, Landers, Gregory, Robertson, Barbara, Ruff, Paul, Schoeman, Elizabeth, Maurel, Jean-Marc, Diez Garcia, Marc, Jimenez Fonseca, Paula, Gallego Plazas, Javier, Rivera Herrero, Fernando, Miranda Poma, Jesus, Layos Romero, Laura, Fritsch, Ralph, Bastian, Sara, Winterhalder, Ralph, Dosso, Sara De, Kossler, Thibaud, Yeh, Kun-Huei, Yen, Chia-Jui, Chen, Yen-Yang, Lin, Johnson, Bilici, Mehmet, Ozguroglu, Mustafa, Cil, Timucin, Oksuzoglu, Berna, Harputluoglu, Hakan, Karaoglu, Aziz, Hacibekiroglu, Ilhan, Erdogan, Bulent, Yalcin, Suayib, Adamchuk, Hryhoriy, Bondarenko, Igor, Kolesnik, Oleksii, Ostapenko, Yuriy, Kryzhanivska, Anna, Leshchenko, Lurii, Ilin, Ievgen, Shparyk, Yaroslav, Trukhin, Dmytro, Voitko, Nataliia, Roy, Rajarshi, Young, Anna-Mary, Medley, Louise, Shiu, Kai-Keen, Celano, Paul, Overton, Lindsay, Raj, Moses, Dunne, Richard, Wainberg, Zev, Dayyani, Farshid, Larson, Timothy, Kochenderfer, Mark, Yañez, Patricio, Rivera, Fernando, Alves, Gustavo Vasconcelos, Garrido, Marcelo, Fernández, Manuel González, Lowery, Maeve A, Çil, Timuçin, Cruz, Felipe Melo, Wainberg, Zev A, Yin, Lina, Bordia, Sonal, Bhagia, Pooja, and Wyrwicz, Lucjan S

Published
2023
Full Text
View/download PDF

21. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours

Author

Hernando, Jorge, Roca-Herrera, Maria, García-Álvarez, Alejandro, Raymond, Eric, Ruszniewski, Philippe, Kulke, Matthew H., Grande, Enrique, García-Carbonero, Rocío, Castellano, Daniel, Salazar, Ramón, Ibrahim, Toni, Teule, Alex, Alonso, Vicente, Fazio, Nicola, Valle, Juan W., Tafuto, Salvatore, Carmona, Ana, Navarro, Victor, and Capdevila, Jaume

Published
2023
Full Text
View/download PDF

23. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Author

Van Cutsem, Eric, Tempero, Margaret A, Sigal, Darren, Oh, Do-Youn, Fazio, Nicola, Macarulla, Teresa, Hitre, Erika, Hammel, Pascal, Hendifar, Andrew E, Bates, Susan E, Li, Chung-Pin, Hingorani, Sunil R, de la Fouchardiere, Christelle, Kasi, Anup, Heinemann, Volker, Maraveyas, Anthony, Bahary, Nathan, Layos, Laura, Sahai, Vaibhav, Zheng, Lei, Lacy, Jill, Park, Joon Oh, Portales, Fabienne, Oberstein, Paul, Wu, Wilson, Chondros, Dimitrios, and Bullock, Andrea J

Subjects
Clinical Research, Rare Diseases, Clinical Trials and Supportive Activities, Pancreatic Cancer, Digestive Diseases, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Albumins, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Deoxycytidine, Disease Progression, Double-Blind Method, Fatigue, Female, Humans, Hyaluronic Acid, Hyaluronoglucosaminidase, Hyponatremia, Male, Middle Aged, Paclitaxel, Pancreatic Neoplasms, Progression-Free Survival, Response Evaluation Criteria in Solid Tumors, Spasm, Survival Rate, HALO 109-301 Investigators, Gemcitabine, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (PDA).Patients and methodsHALO 109-301 was a phase III, randomized, double-blind, placebo-controlled study. Patients ≥ 18 years of age with untreated, metastatic, hyaluronan-high PDA were randomly assigned 2:1 to PEGPH20 plus AG or placebo plus AG. Treatment was administered intravenously in 4-week cycles (3 weeks on, 1 week off) until progression or intolerable adverse events: PEGPH20 3.0 µg/kg twice per week for cycle 1 and once per week thereafter; nab-paclitaxel 125 mg/m2 once per week; and gemcitabine 1,000 mg/m2 once per week. The primary end point was overall survival (OS); secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety. Response was independently assessed per RECIST v1.1.ResultsAt data cutoff, 494 patients were randomly assigned, with 492 (327 for PEGPH20 and 165 for placebo) included in intention-to-treat analyses. Baseline characteristics were balanced for PEGPH20 plus AG versus placebo plus AG. There were 330 deaths, with a median OS of 11.2 months for PEGPH20 plus AG versus 11.5 months for placebo plus AG (hazard ratio [HR], 1.00; 95% CI, 0.80 to 1.27; P = .97); median PFS was 7.1 months versus 7.1 months (HR, 0.97 [95% CI, 0.75 to 1.26]); ORR was 47% versus 36% (ORR ratio, 1.29 [95% CI, 1.03 to 1.63]). Grade ≥ 3 adverse events with a ≥ 2% higher rate with PEGPH20 plus AG than with placebo plus AG included fatigue (16.0% v 9.6%), muscle spasms (6.5% v 0.6%), and hyponatremia (8.0% v 3.8%).ConclusionThe addition of PEGPH20 to AG increased the ORR but did not improve OS or PFS. The safety profile of PEGPH20 plus AG was consistent with that found in previous studies. These results do not support additional development of PEGPH20 in metastatic PDA.

Published
2020

26. New Approaches in Medical Therapies

Author

Rubino, Manila, Spada, Francesca, Laffi, Alice, Fazio, Nicola, Beretta, Giordano, editor, Berruti, Alfredo, editor, Bombardieri, Emilio, editor, Fazio, Nicola, editor, and Goletti, Orlando, editor

Published
2021
Full Text
View/download PDF

28. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer

Author

Ciardiello, Davide, primary, Martinelli, Erika, additional, Troiani, Teresa, additional, Mauri, Gianluca, additional, Rossini, Daniele, additional, Martini, Giulia, additional, Napolitano, Stefania, additional, Famiglietti, Vincenzo, additional, Del Tufo, Sara, additional, Masi, Gianluca, additional, Santini, Daniele, additional, Avallone, Antonio, additional, Pietrantonio, Filippo, additional, Lonardi, Sara, additional, Di Maio, Massimo, additional, Zampino, Maria Giulia, additional, Fazio, Nicola, additional, Bardelli, Alberto, additional, Siena, Salvatore, additional, Cremolini, Chiara, additional, Sartore-Bianchi, Andrea, additional, and Ciardiello, Fortunato, additional

Published
2024
Full Text
View/download PDF

29. Corrigendum to “Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours” [Eur J Cancer 188 (2023) 39–48]

Author

Hernando, Jorge, primary, Roca-Herrera, Maria, additional, García-Álvarez, Alejandro, additional, Raymond, Eric, additional, Ruszniewski, Philippe, additional, Kulke, Matthew H., additional, Grande, Enrique, additional, Carbonero, Rocío García, additional, Castellano, Daniel, additional, Salazar, Ramón, additional, Ibrahim, Toni, additional, Teule, Alex, additional, Alonso, Vicente, additional, Fazio, Nicola, additional, Valle, Juan W., additional, Tafuto, Salvatore, additional, Carmona, Ana, additional, Navarro, Victor, additional, and Capdevila, Jaume, additional

Published
2024
Full Text
View/download PDF

32. Author Correction: GZMKhigh CD8+ T effector memory cells are associated with CD15high neutrophil abundance in non-metastatic colorectal tumors and predict poor clinical outcome

Author

Tiberti, Silvia, Catozzi, Carlotta, Croci, Ottavio, Ballerini, Mattia, Cagnina, Danilo, Soriani, Chiara, Scirgolea, Caterina, Gong, Zheng, He, Jiatai, Macandog, Angeli D., Nabinejad, Amir, Nava Lauson, Carina B., Quinte’, Arianna, Bertalot, Giovanni, Petz, Wanda L., Ravenda, Simona P., Licursi, Valerio, Paci, Paola, Rasponi, Marco, Rotta, Luca, Fazio, Nicola, Ren, Guangwen, Fumagalli-Romario, Uberto, Schaefer, Martin H., Campaner, Stefano, Lugli, Enrico, Nezi, Luigi, and Manzo, Teresa

Published
2022
Full Text
View/download PDF

33. GZMKhigh CD8+ T effector memory cells are associated with CD15high neutrophil abundance in non-metastatic colorectal tumors and predict poor clinical outcome

Author

Tiberti, Silvia, Catozzi, Carlotta, Croci, Ottavio, Ballerini, Mattia, Cagnina, Danilo, Soriani, Chiara, Scirgolea, Caterina, Gong, Zheng, He, Jiatai, Macandog, Angeli D., Nabinejad, Amir, Nava Lauson, Carina B., Quinte’, Arianna, Bertalot, Giovanni, Petz, Wanda L., Ravenda, Simona P., Licursi, Valerio, Paci, Paola, Rasponi, Marco, Rotta, Luca, Fazio, Nicola, Ren, Guangwen, Fumagalli-Romario, Uberto, Schaefer, Martin H., Campaner, Stefano, Lugli, Enrico, Nezi, Luigi, and Manzo, Teresa

Published
2022
Full Text
View/download PDF

34. Neuroendocrine Neoplasms (NENs)

Author

Fazio, Nicola, Spada, Francesca, Rossi, Roberta Elisa, Ambrosini, Valentina, Incorvaia, Lorena, Passiglia, Francesco, Cani, Massimiliano, Badalamenti, Giuseppe, Riva Sanseverino, Eleonora, Editor-in-Chief, Amenta, Carlo, Series Editor, Carapezza, Marco, Series Editor, Chiodi, Marcello, Series Editor, Laghi, Andrea, Series Editor, Maresca, Bruno, Series Editor, Micale, Giorgio Domenico Maria, Series Editor, Mocciaro Li Destri, Arabella, Series Editor, Öchsner, Andreas, Series Editor, Piva, Mariacristina, Series Editor, Russo, Antonio, Series Editor, Seel, Norbert M., Series Editor, Peeters, Marc, editor, Incorvaia, Lorena, editor, and Rolfo, Christian, editor

Published
2021
Full Text
View/download PDF

35. The Right to Oncological Oblivion: A Legislative Response to Cancer Survivor Discrimination in Italy.

Author

D'Antonio, Gianpiero, Bolino, Ginevra, Sorace, Letizia, Volonnino, Gianpietro, Pellegrini, Lavinia, Di Fazio, Nicola, and Frati, Paola

Subjects
INSURANCE, EUROPEANS, LEGISLATION, CANCER patients, HUMAN rights, DISCRIMINATION (Sociology), EMPLOYMENT discrimination, BANKING industry, ADOPTION, SOCIAL stigma
Abstract

Despite the increasing efficacy of modern medicine in diagnosing and treating cancer, survivors often face discrimination in employment, economics, insurance, and society. Law no. 193/2023, also known as the "Oncological Oblivion Law", aims to provide an initial legislative response to discrimination against cancer survivors in Italy. After defining oncological oblivion in Article 1, the Law provides, in Articles 2, 3, and 4, directives to prevent discrimination against cancer survivors in the area of access to banking and insurance services, adoption procedures and access to or retention in employment. The aim of this work is to illustrate the content and the critical aspects of the recent Law 193/2023 in the landscape of European directives. The legislative process at the Chamber of Deputies and the Senate of the Italian Republic has been retraced through the consultation of preparatory works and bills registered on institutional databases. Law 193/2023 represents the first initiative in Italy aimed at the recognition of the right to oncological oblivion, not only in access to banking and insurance services as in other countries, but also in adoption, employment, and re-employment. Our opinion piece highlights the need for further clarification and expansion to prevent discrimination and protect the social–work–relational rights of people who have been affected by oncological diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Pneumonectomy for broncho-pulmonary carcinoids: a single centre analysis of surgical approaches and patient outcomes.

Author

Diotti, Cristina, Bertolaccini, Luca, Girelli, Lara, Uslenghi, Clarissa, Donghi, Stefano Maria, Guarize, Juliana, Spada, Francesca, Fazio, Nicola, and Spaggiari, Lorenzo

Subjects
NEUROENDOCRINE tumors, LYMPHADENECTOMY, SURGICAL complications, OPERATIVE surgery, OVERALL survival, PNEUMONECTOMY, CARCINOID
Abstract

Background: Pneumonectomy is a radical surgical procedure associated with significant morbidity and mortality. Its application in the context of pulmonary neuroendocrine tumours, including carcinoid tumours, requires meticulous preoperative planning and intraoperative precision. This study aims to assess the safety and efficacy of pneumonectomy in the management of these rare and challenging neoplasms. Methods: A retrospective analysis of patients who underwent pneumonectomy for pulmonary carcinoid tumours at our institution over a specified period was conducted. Data regarding patient demographics, tumour characteristics, surgical techniques, intraoperative complications, perioperative management, and long-term outcomes were collected and analysed. Results: Between March 2001 and October 2022, 21 patients (7 male, 14 female) with carcinoid tumours underwent pneumonectomy on a total of 459 surgical operations for carcinoid. Preoperative bronchoscopic procedures were conducted in 90.4% of cases, leading to histological diagnoses for most. The median hospital stay was eight days, with no reported perioperative deaths. Median follow-up after surgery was 73 months, with a five-year overall survival of 65.4 months. Recurrences occurred in 28.6% of cases, primarily in atypical carcinoids. Conclusion: Despite the rarity of bronchial carcinoids, pneumonectomy is effective for low-grade malignancies, demonstrating positive short—and longterm outcomes. Radical lymph node dissection is fundamental in pathological staging and overall survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Reliability of clinical judgment for evaluation of informed consent in mental health settings and the validation of the Evaluation of Informed Consent to Treatment (EICT) scale

Author

Di Fazio, Nicola, primary, Morena, Donato, additional, Piras, Federica, additional, Piras, Fabrizio, additional, Banaj, Nerisa, additional, Delogu, Giuseppe, additional, Damato, Felice, additional, Frati, Paola, additional, Fineschi, Vittorio, additional, Ferracuti, Stefano, additional, Sani, Gabriele, additional, and Dacquino, Claudia, additional

Published
2024
Full Text
View/download PDF

38. Oxidative Stress in Sepsis: A Focus on Cardiac Pathology

Author

Bertozzi, Giuseppe, primary, Ferrara, Michela, additional, Di Fazio, Aldo, additional, Maiese, Aniello, additional, Delogu, Giuseppe, additional, Di Fazio, Nicola, additional, Tortorella, Vittoria, additional, La Russa, Raffaele, additional, and Fineschi, Vittorio, additional

Published
2024
Full Text
View/download PDF

39. Venous thromboembolism in pancreatic neuroendocrine neoplasm: a cohort study

Author

Gervaso, Lorenzo, primary, Laffi, Alice, additional, Gaeta, Aurora, additional, Gandini, Sara, additional, Boldrini, Laura, additional, Meneses-Medina, Monica Isabel, additional, Rubino, Manila, additional, Benini, Lavinia, additional, Borghesani, Michele, additional, Algeri, Laura, additional, Curigliano, Giuseppe, additional, Spada, Francesca, additional, Cella, Chiara Alessandra, additional, and Fazio, Nicola, additional

Published
2024
Full Text
View/download PDF

43. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Author

Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R., La Salvia, Anna, Hofland, Johannes, Hernando, Jorge, Sonbol, Mohamad B., Garcia-Carbonero, Rocio, Capdevila, Jaume, de Herder, Wouter W., Koumarianou, Anna, Kaltsas, Gregory, Rossi, Maura, Grozinsky-Glasberg, Simona, Oleinikov, Kira, Boselli, Sabrina, Tamayo, Darina, Bagnardi, Vincenzo, Laffi, Alice, Rubino, Manila, and Spada, Francesca

Published
2021
Full Text
View/download PDF

46. Capacity to Consent in Healthcare: A Systematic Review and Meta-Analysis Comparing Patients with Bipolar Disorders and Schizophrenia Spectrum Disorders.

Author

Morena, Donato, Lippi, Matteo, Di Fazio, Nicola, Delogu, Giuseppe, Rinaldi, Raffaella, Frati, Paola, and Fineschi, Vittorio

Subjects
SCHIZOPHRENIA, BIPOLAR disorder, ADVANCE directives (Medical care), MEDICAL personnel, MEDICAL care
Abstract

Background: Mental capacity is a fundamental aspect that enables patients to fully participate in various healthcare procedures. To assist healthcare professionals (HCPs) in assessing patients' capacity, especially in the mental health field, several standardized tools have been developed. These tools include the MacArthur Competence Assessment Tool for Treatment (MacCAT-T), the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR), and the Competence Assessment Tool for Psychiatric Advance Directives (CAT-PAD). The core dimensions explored by these tools include Understanding, Appreciation, Reasoning, and Expression of a choice. Objective: This meta-analysis aimed to investigate potential differences in decision-making capacity within the healthcare context among groups of patients with bipolar disorders (BD) and schizophrenia spectrum disorders (SSD). Methods: A systematic search was conducted on Medline/Pubmed, and Scopus. Additionally, Google Scholar was manually inspected, and a manual search of emerging reviews and reference lists of the retrieved papers was performed. Eligible studies were specifically cross-sectional, utilizing standardized assessment tools, and involving patients diagnosed with BD and SSD. Data from the studies were independently extracted and pooled using random-effect models. Hedges' g was used as a measure for outcomes. Results: Six studies were identified, with three studies using the MacCAT-CR, two studies the MacCAT-T, and one the CAT-PAD. The participants included 189 individuals with BD and 324 individuals with SSD. The meta-analysis revealed that patients with BD performed slightly better compared to patients with SSD, with the difference being statistically significant in the domain of Appreciation (ES = 0.23, 95% CI: 0.01 to 0.04, p = 0.037). There was no statistically significant difference between the two groups for Understanding (ES = 0.09, 95% CI:−0.10 to 0.27, p = 0.352), Reasoning (ES = 0.18, 95% CI: −0.12 to 0.47, p = 0.074), and Expression of a choice (ES = 0.23, 95% CI: −0.01 to 0.48, p = 0.60). In the sensitivity analysis, furthermore, when considering only studies involving patients in symptomatic remission, the difference for Appreciation also resulted in non-significant (ES = 0.21, 95% CI: −0.04 to 0.46, p = 0.102). Conclusions: These findings indicate that there are no significant differences between patients with BD and SSD during remission phases, while differences are minimal during acute phases. The usefulness of standardized assessment of capacity at any stage of the illness should be considered, both for diagnostic-therapeutic phases and for research and advance directives. Further studies are necessary to understand the reasons for the overlap in capacity between the two diagnostic categories compared in this study. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group

Author

Fazio, Nicola, primary, Falconi, Massimo, additional, Foglia, Emanuela, additional, Bartolomei, Mirco, additional, Berruti, Alfredo, additional, D’Onofrio, Mirko, additional, Ferone, Diego, additional, Giordano, Alessandro, additional, Grimaldi, Franco, additional, Milione, Massimo, additional, Panzuto, Francesco, additional, Santimaria, Monica, additional, Schillaci, Orazio, additional, Seregni, Ettore, additional, Stasi, Michele, additional, Volante, Marco, additional, and Lastoria, Secondo, additional

Published
2023
Full Text
View/download PDF

49. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Rha, Sun Young, primary, Oh, Do-Youn, additional, Yañez, Patricio, additional, Bai, Yuxian, additional, Ryu, Min-Hee, additional, Lee, Jeeyun, additional, Rivera, Fernando, additional, Alves, Gustavo Vasconcelos, additional, Garrido, Marcelo, additional, Shiu, Kai-Keen, additional, Fernández, Manuel González, additional, Li, Jin, additional, Lowery, Maeve A, additional, Çil, Timuçin, additional, Cruz, Felipe Melo, additional, Qin, Shukui, additional, Luo, Suxia, additional, Pan, Hongming, additional, Wainberg, Zev A, additional, Yin, Lina, additional, Bordia, Sonal, additional, Bhagia, Pooja, additional, Wyrwicz, Lucjan S, additional, Mendez, Guillermo, additional, O'Connor, Juan Manuel, additional, Yanzi Castilla, Alvaro, additional, Cundom, Juan, additional, Kaen, Diego, additional, Wong, Rachel, additional, Ng, Weng, additional, Aghmesheh, Morteza, additional, Peressoni, Mauricio, additional, Andrade, Carlos, additional, Franke, Fabio, additional, Alves, Gustavo, additional, Cruz, Felipe Jose, additional, Vianna, Karina, additional, Monteiro, Maria Marcela, additional, Raphael, Michael, additional, Berry, Scott, additional, Jang, Raymond, additional, Tan, Ann, additional, Asselah, Jamil, additional, Yanez Weber, Patricio, additional, Mahave, Mauricio, additional, Sanchez, Cesar, additional, Salman, Pamela, additional, Zhang, Xiaochun, additional, Liu, Tianshu, additional, Lin, Xiaoyan, additional, Yang, Jianwei, additional, Li, Wei, additional, Ying, Jieer, additional, Chen, Xi, additional, Zeng, Shan, additional, Qu, Yanli, additional, Yang, Lin, additional, Zhao, Lin, additional, Chen, Ping, additional, Li, Enxiao, additional, Ye, Feng, additional, Lu, Jianwei, additional, Liang, Xinjun, additional, Zhao, Qun, additional, Yin, Xianli, additional, Li, Junhe, additional, Ling, Yang, additional, Lv, Guoqing, additional, Li, Shouguo, additional, Guerrero, Alvaro, additional, Rubiano, Juan, additional, Gonzalez Fernandez, Manuel, additional, Manneh Kopp, Ray, additional, Guzman Ramirez, Adrian, additional, Corrales, Luis, additional, Gonzalez Herrera, Ileana, additional, Melichar, Bohuslav, additional, Buchler, Tomas, additional, Svoboda, Tomas, additional, Obermannova, Radka, additional, Vrana, David, additional, Cvek, Jakub, additional, Pfeiffer, Per, additional, Baeksgaard, Lene, additional, Yilmaz, Mette, additional, Boige, Valerie, additional, Lopez-Trabada, Daniel, additional, Borg, Christophe, additional, Pannier, Diane, additional, Hiret, Sandrine, additional, Di Fiore, Frederic, additional, Metges, Jean-Philippe, additional, Arnold, Dirk, additional, Martens, Uwe, additional, Lordick, Florian, additional, Stein, Alexander, additional, Castro, Hugo, additional, Lopez, Karla, additional, Ramirez, Julio, additional, Aguilar, Mynor, additional, Chivalan, Marco, additional, Chan, Wendy, additional, Cheng, Ashley, additional, Yeo, Winnie, additional, Arkosy, Peter, additional, Csoszi, Tibor, additional, Hitre, Erika, additional, Horvath, Zsolt, additional, Lowery, Maeve, additional, McDermott, Ray, additional, Morris, Patrick, additional, Hubert, Ayala, additional, Brenner, Baruch, additional, Ben-Aharon, Irit, additional, Shacham-Shmueli, Einat, additional, Man, Sofia, additional, Pelles Avraham, Sharon, additional, Brenner, Ronen, additional, Mishaeli, Moshe, additional, Di Bartolomeo, Maria, additional, Fazio, Nicola, additional, Lonardi, Sara, additional, Garufi, Carlo, additional, Satoh, Taroh, additional, Hara, Hiroki, additional, Iwagami, Shiro, additional, Yasui, Hisateru, additional, Tsuda, Masahiro, additional, Shimoyama, Tatsu, additional, Shoji, Hirokazu, additional, Sugimoto, Naotoshi, additional, Shibata, Nobuhiro, additional, Yamaguchi, Kensei, additional, Amagai, Kenji, additional, Choda, Yasuhiro, additional, Esaki, Taito, additional, Yabusaki, Hiroshi, additional, Oshima, Takashi, additional, Tsuji, Akihito, additional, Kawakami, Hisato, additional, Kawazoe, Akihito, additional, Ishido, Kenji, additional, Kadowaki, Shigenori, additional, Martinez Rodriguez, Jorge, additional, Herrera Martinez, Marytere, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Balancan, Paola, additional, Damianovich, Dragan, additional, Castro Oliden, Victor, additional, Grados, Julio, additional, Torres, Cesar, additional, Wyrwicz, Lucjan, additional, Wysocki, Piotr, additional, Hajac, Lukasz, additional, Zolnierek, Jakub, additional, Karaszewska, Boguslawa, additional, Rha, Sun Young, additional, Orlova, Rashida, additional, Tjulandin, Sergey, additional, Fadeeva, Natalia, additional, Makarycheva, Yulia, additional, Nosov, Dmitry, additional, Smagina, Maria, additional, Chan, Sze, additional, Jacobs, Conrad, additional, Kraus, Peter, additional, Landers, Gregory, additional, Robertson, Barbara, additional, Ruff, Paul, additional, Schoeman, Elizabeth, additional, Maurel, Jean-Marc, additional, Diez Garcia, Marc, additional, Jimenez Fonseca, Paula, additional, Gallego Plazas, Javier, additional, Rivera Herrero, Fernando, additional, Miranda Poma, Jesus, additional, Layos Romero, Laura, additional, Fritsch, Ralph, additional, Bastian, Sara, additional, Winterhalder, Ralph, additional, Dosso, Sara De, additional, Kossler, Thibaud, additional, Yeh, Kun-Huei, additional, Yen, Chia-Jui, additional, Chen, Yen-Yang, additional, Lin, Johnson, additional, Bilici, Mehmet, additional, Ozguroglu, Mustafa, additional, Cil, Timucin, additional, Oksuzoglu, Berna, additional, Harputluoglu, Hakan, additional, Karaoglu, Aziz, additional, Hacibekiroglu, Ilhan, additional, Erdogan, Bulent, additional, Yalcin, Suayib, additional, Adamchuk, Hryhoriy, additional, Bondarenko, Igor, additional, Kolesnik, Oleksii, additional, Ostapenko, Yuriy, additional, Kryzhanivska, Anna, additional, Leshchenko, Lurii, additional, Ilin, Ievgen, additional, Shparyk, Yaroslav, additional, Trukhin, Dmytro, additional, Voitko, Nataliia, additional, Roy, Rajarshi, additional, Young, Anna-Mary, additional, Medley, Louise, additional, Celano, Paul, additional, Overton, Lindsay, additional, Raj, Moses, additional, Dunne, Richard, additional, Wainberg, Zev, additional, Dayyani, Farshid, additional, Larson, Timothy, additional, and Kochenderfer, Mark, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results